Nuntius
In vitro transcription by T7 RNA polymerase leads to the formation of double-stranded RNA (dsRNA), which is highly immunogenic.
Indeed, dsRNA activates TLR3, RIG-I and MDA5. Transduction signals from these receptors trigger the release of type I-interferon, as well as pro-inflammatory cytokines. Besides, dsRNA activates PKR and OAS leading to translation repression of transfected mRNA.
Different approaches have been developed to reduce the dsRNA concentration of mRNA solutions. However, dsRNA is not removed.
Nuntius biotechnology involves efficiently capturing dsRNA from an mRNA solution. Messenger Biopharma was able to decrease the concentration of dsRNA by more than 850 times.
Nuntius is compatible with other approaches aimed at reducing the concentration of dsRNA. These can alternatively be replaced by Nuntius.
News
OST Group becomes a shareholder in July 2019
July 08, 2019
©copyright 2016 Coqpit